<![CDATA[A case-control study was carried out in Kirkuk city from March to July 2019. The number of pregnantwomen (with gestational diabetes) understudy were 50 whose ages were between 17-42 years old to estimatethe level of visfatin and chemerin in pregnant women with gestational diabetes. These patients attended toKirkuk General Hospital to gynecology unit for pregnancy follow up. The control group who were matchedto the pregnant women studied, included 30 healthy non-pregnant women. Blood was collected from eachpatient and control enrolled in this study for assessment of HbA1c, blood glucose level, visfatin and chemerinlevels. The study showed no significant difference between studied cases and the control group regardingpatient age and gestational age at sampling and parity (P>0.05) while there was a significant differencebetween studied cases and the control group regarding systolic and diastolic blood pressure. The studyshowed that the highest mean level of visfatin was found in pregnant women with gestational diabetescomparing with healthy control ( 14.6±3.11 v.s. 7.81±3.01ng/ml) (P: <0.01). The study showed that thehighest mean level of chemerin was found in pregnant women with gestational diabetes comparing withhealthy control (78.92±18.44 v.s. 78.92±18.44 ng/ml) (P: ?0.05). The study showed that the highest meanlevel of visfatin was found in pregnant women who have elevated level of glucose and HbA1c (5.75±3.81and 5.91±3.67 ng/ml) respectively, as compared with patients with normal level of glucose and HbA1c(4.61±2.99 and 3.95±2.12 ng/ml) respectively (P: ?0.01). The study showed that the highest mean levelof visfatin was found in pregnant women who have elevated level of glucose and HbA1c (148.9±25.7and 158.6±23.5 ng/ml) respectively, as compared with patients with normal level of glucose and HbA1c(111.5±14.6 and 105.1±15.7 ng/ml) respectively (P: ?0.05). The study concluded that, there was a highlysignificant relation of visfatin and chemerin with gestational diabetes mellitus in pregnant women]]>
